Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIO window study of rucaparib in primary triple-negative or BRCA1/2-related breast cancer
2014-003319-12Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib in breast cancer, triple-negative breast cancer (TNBC) and Hereditary Breast Cancer, sponsored by Royal Marsden NHS Foundation Trust. Started Feb 2015; status: completed.
02
Drugs
rucaparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)Hereditary Breast Cancer
Beyond the preview
Go deeper on 2014-003319-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003319-12.